2,600,000 Shares HUBBELL INCORPORATED Class B Common Stock, Par Value $.01 UNDERWRITING AGREEMENT
Exhibit 1.1
Execution Version
2,600,000 Shares
XXXXXXX INCORPORATED
Class B Common Stock, Par Value $.01
October 28, 2009
October 28, 2009
Xxxxxx Xxxxxxx & Co. Incorporated
X.X. Xxxxxx Securities Inc.
X.X. Xxxxxx Securities Inc.
As Representatives of the
several Underwriters listed
in Schedule I hereto
several Underwriters listed
in Schedule I hereto
c/o Morgan Xxxxxxx & Co. Incorporated
0000 Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Xxx Xxxx, Xxx Xxxx 00000
X.X. Xxxxxx Securities Inc.
000 Xxxxxxx Xxx
Xxx Xxxx, Xxx Xxxx 00000
000 Xxxxxxx Xxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Xxxxxxx Incorporated, a Connecticut corporation (the “Company”), proposes to issue and sell to
the several Underwriters named in Schedule I hereto (the “Underwriters”) 2,600,000 shares of its
Class B Common Stock, par value $.01 (the “Firm Shares”). The Company also proposes to issue and
sell to the several Underwriters not more than an additional 390,000 shares of its Class B Common
Stock, par value $.01 (the “Additional Shares”), if and to the extent that you, as Representatives
of the Underwriters (the “Representatives”), shall have determined to exercise, on behalf of the
Underwriters, the right to purchase such shares of Class B Common Stock granted to the Underwriters
in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively
referred to as the “Shares.” The shares of Class B Common Stock, par value $.01, of the Company to
be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as
the “Class B Common Stock.” The Class B Common Stock, together with the shares of Class A Common
Stock, par value $.01, per share, of the Company (the “Class A Common Stock”) to be outstanding
after giving effect to the sales contemplated hereby are hereinafter referred to, collectively, as
the “Common Stock.”
The Company has filed with the Securities and Exchange Commission (the “Commission”) a
registration statement on Form S-3 (File No. 333-151206), including a prospectus, relating to the
Shares. The registration statement at the time it became effective, including the information, if
any, deemed to be part of
the registration statement at the time of effectiveness, including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C (“Rule 430 Information”) under the
Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder
(collectively, the “Securities Act”), is hereinafter referred to as the “Registration Statement”;
the base prospectus filed as part of the Registration Statement, in the form in which it was most
recently filed with the Commission prior to or on the date of this underwriting agreement (this
“Agreement”), is referred to herein as the “Base Prospectus”; and the final
prospectus supplement in the form first used to confirm sales of Shares (or in the form first
made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule
173 under the Securities Act) (together with the Base Prospectus) is hereinafter referred to as the
“Prospectus.”
For purposes of this Agreement, “free writing prospectus” has the meaning set forth in Rule
405 under the Securities Act, “Time of Sale Prospectus” means the preliminary prospectus,
identified in Schedule II hereto, together with the free writing prospectuses, if any, each
identified in Schedule II hereto and the information set forth on the Rule 134 term sheet, attached
as Exhibit A hereto, and “broadly available road show” means a “bona fide electronic road show” as
defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction
to any person. As used herein, the terms “Registration Statement,” “Base Prospectus,” “preliminary
prospectus,” “Time of Sale Prospectus” and “Prospectus” shall include the documents incorporated by
reference therein on or before the effective date of the Registration Statement or the date of such
Time of Sale Prospectus (as defined below) or the Prospectus, as the case may be. The terms
“supplement,” “amendment” and “amend” as used herein with respect to the Registration Statement,
the Base Prospectus, preliminary prospectus, the Time of Sale Prospectus, the Prospectus or any
free writing prospectus shall include all documents subsequently filed by the Company with the
Commission pursuant to the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission thereunder (collectively, the “Exchange Act”), after the effective
date of the Registration Statement or the date of such Time of Sale Prospectus or the Prospectus,
as the case may be, and under the Exchange Act that are deemed to be incorporated by reference
therein.
1. Representations, Warranties and Agreements. The Company represents and warrants to, and
agrees with each of the Underwriters that:
(a) The Registration Statement is an “automatic shelf registration statement” (as defined in
Rule 405 under the Securities Act) that has been filed with the Commission not earlier than three
years prior to the date hereof. No order suspending the effectiveness of the Registration
Statement or preventing or suspending the use of the Time of Sale Prospectus or any other
preliminary prospectus has been issued by the Commission, and no proceeding for that
2
purpose or
pursuant to Section 8A of the Securities Act against the Company or related to the offering has
been initiated or threatened by the Commission; and no notice of objection of the Commission to the
use of the Registration Statement or any post-effective amendment thereto pursuant to Rule
401(g)(2) under the Securities Act has been received by the Company.
(b) (i) Each document filed or to be filed pursuant to the Exchange Act and incorporated by
reference in the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in
all material respects with the Exchange Act, (ii) the Registration Statement, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (iii) the Registration
Statement, the Time of Sale Prospectus and the Prospectus comply and, as amended or
supplemented, if applicable, will comply in all material respects with the Securities Act, (iv) the
Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the
offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date
(as defined in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the
Company, if applicable, will not, contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, (v) each broadly available road show, if any, when considered
together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading and (vi) the Prospectus does not contain
and, as amended or supplemented, if applicable, will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Registration
Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any
Underwriter furnished to the Company in writing by such Underwriter through you expressly for use
therein.
(c) The Company is not an “ineligible issuer” in connection with the offering pursuant to
Rules 164, 405 and 433 under the Securities Act and is a “well-known seasoned issuer” (as defined
in Rule 405 under the Securities Act). Any free writing prospectus that the Company is required to
file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the
Commission in accordance with the requirements of the Securities Act. Each free writing prospectus
that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities
Act or that was prepared by or behalf of or used or referred to by the Company complies or will
comply in all material respects with the requirements of the Securities Act. Except for the free
writing prospectuses, if
3
any, identified in Schedule II hereto, and electronic road shows, if any,
each furnished to you before first use, the Company has not prepared, used or referred to, and will
not, without your prior consent, prepare, use or refer to, any free writing prospectus.
(d) The Company has been duly incorporated and is validly existing as a corporation in good
standing under the laws of the State of Connecticut; and the Company has the corporate power and
authority to own its property and to conduct its business as described in the Time of Sale
Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in
each jurisdiction in which the conduct of its business or its ownership or leasing of property
requires such qualification, except to the extent that the failure to be so qualified or be in good
standing would not reasonably be expected to have a material adverse effect on the business,
properties, financial position or results of operations of the Company and its subsidiaries, taken
as a whole (“Material Adverse Effect”) .
(e) Each “significant subsidiary” of the Company (as defined in Rule 405 under the Securities
Act) has been duly incorporated, is validly existing as a corporation in good standing under the
laws of the jurisdiction of its incorporation or organization, has the corporate power and
authority to own its property and to conduct its business as described in the Time of Sale
Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in
each jurisdiction in which the conduct of its business or its ownership or leasing of property
requires such qualification, except to the extent that the failure to be so qualified or be in good
standing would not reasonably be expected to have a Material Adverse Effect; and all of the issued
shares of capital stock of each significant subsidiary of the Company have been duly and validly
authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by
the Company, free and clear of all liens, encumbrances, equities or claims, except as otherwise
disclosed in the Time of Sale Prospectus and the Prospectus. The Company’s only significant
subsidiaries are Burndy LLC, Burndy Americas Inc., Xxxxxxx Incorporated (Delaware), Xxxxxxx
Lighting, Inc., Xxxxxxx Power Systems, Inc. and Wepawaug Canada Corp.
(f) This Agreement has been duly authorized, executed and delivered by the Company.
(g) The authorized capital stock of the Company conforms as to legal matters to the
description thereof contained in each of the Time of Sale Prospectus and the Prospectus.
(h) The shares of Common Stock outstanding prior to the issuance of the Shares have been duly
authorized and are validly issued, fully paid and non-assessable.
4
(i) The Shares have been duly authorized and, when issued and delivered in accordance with the
terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of
the Shares will not be subject to any preemptive or similar rights.
(j) Neither the Company nor any of its significant subsidiaries is (i) in violation of its
charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred
that, with notice or lapse of time or both, would constitute such a default, in the due performance
or observance of any term, covenant or condition contained in any agreement or other instrument
binding upon the Company or any of its subsidiaries that is material to the Company and its
subsidiaries, taken as a whole or to which any of the property or assets of the Company or any of
its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order,
rule or regulation of any court or governmental or regulatory agency, authority or body or any
arbitrator, except, in the case of clauses (ii) and (iii) above, for any such default or violation
that would not, singly or in the aggregate, reasonably be expected to have a Material Adverse
Effect.
(k) The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement will not contravene or result in a breach or violation of any of
the terms or provisions of, or constitute a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any property or assets of the Company or any of its
significant subsidiaries pursuant to, applicable law or the certificate of incorporation or
by-laws of the Company or its subsidiaries or any agreement or other instrument binding upon the
Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a
whole, or any judgment, order or decree of any court or governmental or regulatory agency,
authority or body or any arbitrator having jurisdiction over the Company or any subsidiary; and no
consent, approval, authorization or order of, or qualification with, any court or governmental or
regulatory agency, authority or body or any arbitrator is required for the execution and delivery
of this Agreement by the Company and performance by the Company of its obligations hereunder,
except (i) for the registration of the Shares under the Securities Act and (ii) such as may be
required by the securities or Blue Sky laws of the various states in connection with the offer and
sale of the Shares.
(l) There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings,
business or operations of the Company and its subsidiaries, taken as a whole, from that set forth
in the Time of Sale Prospectus.
(m) There are no legal or governmental proceedings pending or, to the knowledge of the
Company, threatened to which the Company or any of its
5
subsidiaries is a party or to which any of
the properties of the Company or any of its subsidiaries is subject (i) other than proceedings
described in the Time of Sale Prospectus and the Prospectus and proceedings that, if determined
adversely to the Company or any of its subsidiaries, would not reasonably be expected to have a
Material Adverse Effect, or on the power or ability of the Company to perform its obligations under
this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus and
the Prospectus or (ii) that are required to be described in the Time of Sale Prospectus and the
Prospectus and are not so described; and there are no statutes, regulations, contracts or other
documents that are required to be described in the Time of Sale Prospectus and the Prospectus or to
be filed as exhibits to the Registration Statement that are not described or filed as required.
(n) Each preliminary prospectus relating to the Shares filed as part of the Registration
Statement as originally filed or as part of any amendment thereto, or filed pursuant to Rule 424
under the Securities Act, complied when so filed in all material respects with the Securities Act.
(o) The Company is not, and after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Time of Sale Prospectus and the Prospectus
will not be, required to register as an “investment company” or an entity “controlled” by an
“investment company” as such terms are defined in the Investment Company Act of 1940, as amended,
and the rules and regulations of the Commission thereunder (collectively, the “Investment Company
Act”).
(p) There are no contracts, agreements or understandings between the Company and any person
granting such person the right to require the Company to file a registration statement under the
Securities Act with respect to any
securities of the Company or to require the Company to include such securities with the Shares
registered pursuant to the Registration Statement.
(q) The Company and its subsidiaries have good and marketable title in fee simple to, or have
valid rights to lease or otherwise use, all items of real and personal property that are material
to the respective businesses of the Company and its subsidiaries, in each case free and clear of
all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not
materially interfere with the use made and proposed to be made of such property by the Company and
its subsidiaries, (ii) would not reasonably be expected to have a Material Adverse Effect or (iii)
are described in the Time of Sale Prospectus and the Prospectus.
(r) The Company and its subsidiaries own or possess adequate rights to use all material
patents, patent applications, trademarks, service marks, trade names, trademark registrations,
service xxxx registrations, copyrights, licenses
6
and know-how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures)
(collectively, “Intellectual Property”) necessary for the conduct of their respective businesses,
except where the failure to own, possess or have the right to use such Intellectual Property would
not, singly or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole; and to the Company’s knowledge, the conduct of their respective
businesses will not conflict in any material respect with any such rights of others, and the
Company and its subsidiaries have not received any notice of any claim of infringement or conflict
with any such rights of others that, singly or in the aggregate, would reasonably be expected to
have a Material Adverse Effect.
(s) The Company and its subsidiaries possess all licenses, certificates, permits and other
authorizations issued by, and have made all declarations and filings with, the appropriate federal,
state, local or foreign governmental or regulatory authorities that are necessary for the ownership
or lease of their respective properties or the conduct of their respective businesses as described
in the Time of Sale Prospectus and the Prospectus, except where the failure to possess or make the
same would not, singly or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and except as described in the Time of Sale Prospectus and the Prospectus or except where
such revocation or modification would not, singly or in the aggregate, reasonably be expected to
have a Material Adverse Effect, neither the Company nor any of its subsidiaries has received notice
of any revocation or modification of any such license, certificate, permit or authorization or has
any reason to believe that any such license, certificate, permit or authorization will not be
renewed in the ordinary course.
(t) Except as would not reasonably be expected to have a Material Adverse Effect, the Company
and its subsidiaries have insurance covering their respective properties, operations, personnel and
businesses, including business interruption insurance, which insurance is in amounts and insures
against such losses and risks as are adequate to protect the Company and its subsidiaries and their
respective businesses; and except as would not reasonably be expected to have a Material Adverse
Effect, neither the Company nor any of its subsidiaries
has (i) received notice from any insurer or agent of such insurer that capital improvements or
other expenditures are required or necessary to be made in order to continue such insurance or (ii)
any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may
be necessary to continue its business.
(u) No labor disturbance by, or dispute with, employees of the Company or any of its
subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened and the
Company is not aware of any existing or imminent labor disturbance by, or dispute with, the
employees of any of its or its
7
subsidiaries’ principal suppliers, contractors or customers, except
as would not reasonably be expected to have a Material Adverse Effect.
(v) (i) The Company and its subsidiaries (a) are, and at all prior times were, in compliance
with any and all applicable foreign, federal, state and local laws and regulations relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (“Environmental Laws”), (b) have received all permits, licenses,
certificates or other approvals required of them under applicable Environmental Laws to conduct
their respective businesses, (c) are in compliance with all terms and conditions of any such
permit, license or approval, and (d) have not received notice of any actual or potential liability
under or relating to any Environmental Laws, including for the investigation or remediation of any
disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and
have no knowledge of any event or condition that would reasonably be expected to result in any such
notice; and (ii) there are no costs or liabilities associated with Environmental Laws of or
relating to the Company or its subsidiaries, except, in the case of each of clauses (i) and (ii)
above, as disclosed in the Time of Sale Prospectus and the Prospectus and where such noncompliance
with Environmental Laws, failure to receive required permits, licenses or other approvals or
failure to comply with the terms and conditions of such permits, licenses or approvals would not,
singly or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(w) PricewaterhouseCoopers LLP, which has certified certain financial statements of the
Company and its subsidiaries, is an independent registered public accounting firm with respect to
the Company and its subsidiaries within the applicable rules and regulations adopted by the
Commission and the Public Company Accounting Oversight Board (United States) and as required by the
Securities Act.
(x) The Company and its subsidiaries have paid all federal, state, local and foreign taxes and
filed all tax returns required to be paid or filed through the date hereof, and there is no tax
deficiency that has been, or could reasonably be expected to be, asserted against the Company or
any of its subsidiaries or any of their respective properties or assets, in each case, except as
otherwise disclosed in the Time of Sale Prospectus and the Prospectus or as would not, singly or in
the aggregate, reasonably be expected to have a Material Adverse Effect.
(y) The Company maintains an effective system of “disclosure controls and procedures” (as
defined in Rule 13a-15(e) of the Exchange Act) that is designed to ensure that information required
to be disclosed by the Company in reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the Commission’s
rules and forms, including controls and procedures designed to ensure that such
8
information is
accumulated and communicated to the Company’s management as appropriate to allow timely decisions
regarding required disclosure. The Company has carried out evaluations of the effectiveness of its
disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.
(z) The Company maintains systems of “internal control over financial reporting” (as defined
in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and
have been designed by, or under the supervision of, its principal executive and principal financial
officers, or persons performing similar functions, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles, including, without
limitation, internal accounting controls sufficient to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific authorizations; (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles and to maintain asset accountability; (iii) access to
assets is permitted only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in
the Time of Sale Prospectus and the Prospectus, there are no material weaknesses or significant
deficiency in the Company’s internal controls.
(aa) Neither the Company nor any of its subsidiaries, nor to the knowledge of any executive
officers of the Company, any affiliate, director, officer, employee, agent or representative of the
Company or of any of its subsidiaries or affiliates, has taken or will take any action in
furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or
giving of money, property, gifts or anything else of value, directly or indirectly, to any
“government official” (including any officer or employee of a government or government-owned or
controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or
candidate for political office) to influence official action or secure an improper advantage; and
the Company and its subsidiaries and, to the Company’s knowledge, its affiliates have conducted
their businesses in compliance with applicable anti-corruption laws and have instituted and
maintain and will continue to maintain policies and procedures designed to promote and achieve
compliance with such laws and with the representation and warranty contained herein, except where
the failure to comply would not have a Material Adverse Effect.
(bb) The operations of the Company and its subsidiaries are and have been conducted at all
times in material compliance with all applicable financial recordkeeping and reporting
requirements, including those of the Bank Secrecy
9
Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions
where the Company and its subsidiaries conduct business, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or
proceeding by or before any court or governmental or regulatory agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.
(cc) (i) None of the Company nor any of its subsidiaries, nor, any director or officer of the
Company or its subsidiaries, is an individual or entity (“Person”) that is, or is owned or
controlled by a Person that is: (A) the subject of any sanctions (“Sanctions”) administered or
enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), nor (B)
located, organized or resident in a country or territory that is the subject of Sanctions
(including, without limitation, Burma/Myanmar, Cuba, Iran, North Korea, Sudan and Syria).
(ii) The Company will not, directly or indirectly, use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or
other Person: (A) to fund or facilitate any activities or business of or with any Person or in any
country or territory that, at the time of such funding or facilitation, is the subject of
Sanctions; or (B) in any other manner that will result in a violation of Sanctions by any Person
(including any Person participating in the offering, whether as underwriter, advisor, investor or
otherwise).
(iii) The Company and each of its subsidiaries has not, for the past five years, knowingly
engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is
or was the subject of Sanctions.
(dd) The Company has not taken, directly or indirectly, any action designed to or that could
reasonably be expected to cause or result in any stabilization or manipulation of the price of the
Common Stock.
(ee) No forward-looking statement (within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act) contained in the Time of Sale Prospectus and the Prospectus has
been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
10
(ff) Nothing has come to the attention of the Company that has caused the Company to believe
that the statistical and market-related data included in the
Time of Sale Prospectus and the Prospectus is not based on or derived from sources that are
reliable and accurate in all material respects.
(gg) There is and has been no failure on the part of the Company or any of the Company’s
directors or officers, in their capacities as such, to comply with any provision of the
Xxxxxxxx-Xxxxx Act of 2002 and the rules and regulations promulgated in connection therewith (the
“Xxxxxxxx-Xxxxx Act”), including Section 402 (related to loans) and Sections 302 and 906 (related
to certifications).
2. Agreements to Sell and Purchase. The Company hereby agrees to sell to the several
Underwriters, and each Underwriter, upon the basis of the representations and warranties herein
contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to
purchase from the Company the respective numbers of Firm Shares set forth in Schedule I hereto
opposite its name at $40.9575 per share (the “Purchase Price”).
On the basis of the representations and warranties contained in this Agreement, and subject to
its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and
the Underwriters shall have the right to purchase, severally and not jointly, up to 390,000
Additional Shares at the Purchase Price; provided, however, that the amount paid by the
Underwriters for any Additional Shares shall be reduced by an amount per share equal to any
dividends declared by the Company and payable on the Firm Shares but not payable on such Additional
Shares. The Representatives may exercise this right on behalf of the Underwriters in whole or from
time to time in part by giving written notice not later than 30 days after the date of this
Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by
the Underwriters and the date on which such shares are to be purchased. Each purchase date must be
at least one business day after the written notice is given and may not be earlier than the closing
date for the Firm Shares nor later than ten business days after the date of such notice.
Additional Shares may be purchased as provided in Section 4 hereof solely for the purpose of
covering over-allotments made in connection with the offering of the Firm Shares. On each day, if
any, that Additional Shares are to be purchased (an “Option Closing Date”), each Underwriter
agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such
adjustments to eliminate fractional shares as you may determine) that bears the same proportion to
the total number of Additional Shares to be purchased on such Option Closing Date as the number of
Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total
number of Firm Shares.
3. Terms of Public Offering. The Company is advised by you that the Underwriters propose to
make a public offering of their respective portions of the
11
Shares as soon after the Registration
Statement and this Agreement have become effective as in your judgment is advisable. The Company
is further advised by you that the Shares are to be offered to the public initially at $43.00 per
share (the “Public Offering Price”) and to certain dealers selected by you at a price that
represents a concession not in excess of $1.161 per share under the Public Offering Price.
4. Payment and Delivery. Payment for the Firm Shares shall be made to the Company in federal
or other funds immediately available in New York City against delivery of such Firm Shares for the
respective accounts of the several Underwriters at 10:00 a.m. (New York City time) on November 3,
2009, or at such other time on the same or such other date, not later than November 10, 2009, as
shall be designated in writing by you. The time and date of such payment are hereinafter referred
to as the “Closing Date.”
Payment for any Additional Shares shall be made to the Company in federal or other funds
immediately available in New York City against delivery of such Additional Shares for the
respective accounts of the several Underwriters at 10:00 a.m. (New York City time) on the date
specified in the corresponding notice described in Section 2 or at such other time on the same or
on such other date, in any event not later than November 27, 2009, as shall be designated in
writing by you.
The Firm Shares and Additional Shares shall be registered in such names and in such
denominations as you shall request in writing not later than one full business day prior to the
Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and
Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the
case may be, for the respective accounts of the several Underwriters, with any transfer taxes
payable in connection with the transfer of the Shares to the Underwriters duly paid, against
payment of the Purchase Price therefor.
5. Conditions to the Underwriters’ Obligations. The obligations of the Company to sell the
Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for
the Shares on the Closing Date are subject to the condition that the Registration Statement is
effective on the date hereof.
The several obligations of the Underwriters are subject to the following further conditions:
(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:
(i) there shall not have occurred any downgrading, nor shall any notice have been
given of any intended or potential downgrading or of
12
any review for a possible change that
does not indicate the direction of the possible change, in the rating accorded any of the
securities of the Company or any of its subsidiaries by any “nationally recognized
statistical rating organization,” as such term is defined for purposes of Rule 436(g)(2)
under the Securities Act; and
(ii) there shall not have occurred any change, or any development involving a
prospective change, in the condition, financial or otherwise, or in the earnings, business
or operations of the Company and its subsidiaries, taken as a whole, from that set forth
in the Time of Sale Prospectus as of the date of this Agreement that, in your judgment, is
material and adverse and that makes it, in your judgment, impracticable to market the
Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.
(b) The Underwriters shall have received on the Closing Date a certificate, dated the Closing
Date and signed by two executive officers of the Company, to the effect set forth in Section
5(a)(i) above and to the effect that the representations and warranties of the Company contained in
this Agreement are true and correct as of the Closing Date and that the Company has complied with
all of the agreements and satisfied all of the conditions on its part to be performed or satisfied
hereunder on or before the Closing Date.
(c) The Underwriters shall have received on the Closing Date an opinion of Xxx Xxxxxx LLP,
Connecticut counsel for the Company, dated the Closing Date and addressed to the Underwriters, in
form and substance reasonably satisfactory to the Representatives, to the effect set forth in
Exhibit B hereto. The opinion of Xxx Xxxxxx LLP referred to in this Section 5(c) shall be rendered
to the Underwriters at the request of the Company and shall so state therein.
(d) The Underwriters shall have received on the Closing Date an opinion and disclosure letter
of Xxxxxx & Xxxxxxx LLP, counsel for the Company, dated the Closing Date and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect
set forth in Exhibit C hereto. The opinion and disclosure letter of Xxxxxx & Xxxxxxx LLP referred
to in this Section 5(d) shall be rendered to the Underwriters at the request of the Company and
shall so state therein.
(e) The Underwriters shall have received on the Closing Date a tax opinion of Xxxxxx & Xxxxxxx
LLP, counsel for the Company, dated the Closing Date and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representatives, to the effect set forth in Exhibit D
hereto. The opinion of Xxxxxx & Xxxxxxx LLP referred to in this Section 5(e) shall be
13
rendered to
the Underwriters at the request of the Company and shall so state therein.
(f) The Underwriters shall have received on the Closing Date an opinion and disclosure letter
of Xxxxxxx Xxxxxxx & Xxxxxxxx LLP, counsel for the Underwriters, dated the Closing Date, with
respect to such matters as you may reasonably request, and such counsel shall have received such
documents and information as it may reasonably request to enable them to pass upon such matters.
(g) The Underwriters shall have received, on each of the date hereof and the Closing Date, a
letter dated the date hereof or the Closing Date, as the case may be, in form and substance
reasonably satisfactory to the Underwriters, from PricewaterhouseCoopers LLP, independent
registered public accounting firm, containing statements and information of the type ordinarily
included in accountants’ “comfort letters” to underwriters with respect to the financial statements
and certain financial information contained in the Registration Statement, the Time of Sale
Prospectus and the Prospectus; provided that the letter delivered on the Closing Date shall use a
“cut-off date” not earlier than the date hereof.
(h) The Underwriters shall have received, prior to or on the date hereof, “lock-up”
agreements, each substantially in the form of Exhibit E hereto,
between you and certain directors and executive officers of the Company relating to sales and
certain other dispositions of shares of Common Stock or certain other securities, and such lock-up
agreements shall be in full force and effect on the Closing Date.
(i) The Shares shall have been duly listed, subject to effective notice of issuance, on the
New York Stock Exchange.
The several obligations of the Underwriters to purchase Additional Shares hereunder are
subject to the delivery to you on the applicable Option Closing Date of such documents as you may
reasonably request with respect to the good standing of the Company, the due authorization and
issuance of the Additional Shares to be sold on such Option Closing Date and other matters related
to the issuance of such Additional Shares.
6. Covenants of the Company. The Company covenants with each Underwriter as follows:
(a) To file the Prospectus with the Commission within the time period specified by Rule 424(b)
and Rule 430B under the Securities Act; to file with the Commission any free writing prospectus to
the extent required, and within the period specified, by Rule 433 under the Securities Act; to file
promptly all reports
14
and any definitive proxy or information statements required to be filed by the
Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act
subsequent to the date of the Prospectus and during the period mentioned in Section 6(g) or 6(h)
below; and to furnish to you in New York City, without charge, prior to 10:00 a.m. (New York City
time) on the business day next succeeding the date of this Agreement and during the period
mentioned in Section 6(g) or 6(h) below, as many copies of the Time of Sale Prospectus, the
Prospectus, the documents incorporated by reference therein and any supplements and amendments
thereto or to the Registration Statement as you may reasonably request.
(b) Before amending or supplementing the Registration Statement, the Time of Sale Prospectus
or the Prospectus, to furnish to you a copy of each such proposed amendment or supplement and not
to file any such proposed amendment or supplement to which you reasonably object, and to file with
the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
further prospectus required to be filed pursuant to such Rule.
(c) To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used or authorized by, or referred to by the Company and not to use, authorize or refer
to any proposed free writing prospectus to which you reasonably object.
(d) To advise you promptly, and confirm such advice in writing, (i) when any amendment to the
Registration Statement has been filed or becomes effective; (ii) when any supplement to the
Prospectus or any amendment to the Prospectus or any free writing prospectus has been filed; (iii)
of any request by the Commission for any amendment to the Registration Statement or any amendment
or supplement to the Prospectus or the receipt of any comments from the Commission relating to the
Registration Statement or any other request by the Commission for any additional information; (iv)
of the issuance by the
Commission of any order suspending the effectiveness of the Registration Statement or
preventing or suspending the use of any preliminary prospectus or the Prospectus or the initiation
or threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act;
(v) of the occurrence of any event within the period mentioned in Section 6(g) or 6(h) below as a
result of which the Prospectus, the Time of Sale Prospectus or any free writing prospectus as then
amended or supplemented would include any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances existing when the Prospectus, the Time of Sale Prospectus or any
free writing prospectus is delivered to a purchaser, not misleading; (vi) of the receipt by the
Company of any notice of objection of the Commission to the use of the Registration Statement or
any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (vii)
of the receipt by the Company of any notice
15
with respect to any suspension of the qualification of
the Shares for offer and sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose; and to use all commercially reasonable efforts to prevent the issuance
of any such order suspending the effectiveness of the Registration Statement, preventing or
suspending the use of any preliminary prospectus or the Prospectus or suspending any such
qualification of the Shares and, if any such order is issued, will obtain as soon as possible the
withdrawal thereof.
(e) Not to take any action that would result in an Underwriter or the Company being required
to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.
(f) To, pursuant to reasonable procedures developed in good faith, retain copies of each free
writing prospectus that is not filed with the Commission in accordance with Rule 433 under the
Securities Act.
(g) If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time
when the Prospectus is not yet available to prospective purchasers and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale
Prospectus conflicts with the information contained in the Registration Statement then on file, or
if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time
of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to any dealer upon request, either
amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time
of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the Time of
Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration
Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.
(h) If, during such period after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to
in Rule 173(a) of the Securities Act) is required by law to be delivered (or required to be
delivered but for Rule 172 under the Securities Act) in connection with sales by an Underwriter or
dealer, any event shall occur or condition exist as a result of which it is necessary to amend or
supplement the Prospectus in order to make the statements therein, in the light of the
circumstances when the Prospectus (or in lieu thereof the notice referred to in
16
Rule 173(a) of the
Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for
the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable
law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the
Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to
which Shares may have been sold by you on behalf of the Underwriters and to any other dealers upon
request, either amendments or supplements to the Prospectus so that the statements in the
Prospectus as so amended or supplemented will not, in the light of the circumstances when the
Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is
delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will
comply with applicable law.
(i) To qualify the Shares for offer and sale under the securities or Blue Sky laws of such
jurisdictions as you shall reasonably request and to continue such qualifications in effect so long
as required for distribution of the Shares; provided that the Company shall not be required to (i)
qualify as a foreign corporation or other entity or as a dealer in securities in any such
jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent
to service of process in any such jurisdiction or (iii) subject itself to taxation in any such
jurisdiction if it is not otherwise so subject.
(j) To make generally available to the Company’s security holders and to you as soon as
practicable an earning statement covering a period of at least twelve months beginning with the
first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy
the provisions of Section 11(a) and Rule 158 of the Securities Act.
(k) To apply the net proceeds from the sale of the Shares as described in the Time of Sale
Prospectus and the Prospectus under the caption “Use of Proceeds.”
(l) Not to take, directly or indirectly, any action designed to or that could reasonably be
expected to cause or result in any stabilization or manipulation of the price of the Common Stock.
(m) To pay the required Commission filing fees related to the Shares within the time required
by Rule 456(b)(1) under the Securities Act without regard to the proviso therein and otherwise in
accordance with Rule 456(b) and 457(r) under the Securities Act.
(n) Whether or not the transactions contemplated in this Agreement are consummated or this
Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its
obligations under this Agreement, including: (i) the fees, disbursements and expenses of the
Company’s counsel and
17
the Company’s independent registered public accounting firm in connection
with the registration and delivery of the Shares under the Securities Act and all other fees or
expenses in connection with the preparation and filing of the Registration Statement, any
preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus
prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements
to any of the foregoing, including all printing costs associated therewith, and the mailing and
delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove
specified, (ii) all costs and expenses related to the transfer and delivery of the Shares to the
Underwriters, including any transfer or other taxes payable thereon, (iii) the cost of printing or
producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the
Shares under state securities laws and all expenses in connection with the qualification of the
Shares for offer and sale under state securities laws as provided in Section 6(i) hereof, including
filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection
with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv)
all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred
in connection with the review and qualification of the offering of the Shares by the Financial
Industry Regulatory Authority, (v) all costs and expenses incident to listing the Shares on the New
York Stock Exchange, (vi) the cost of printing certificates representing the Shares, (vii) the
costs and charges of any transfer agent, registrar or depositary, (viii) the costs and expenses of
the Company relating to investor presentations on any “road show” undertaken in connection with the
marketing of the offering of the Shares, including, without limitation, expenses associated with
the preparation or dissemination of any electronic road show, expenses associated with the
production of road show slides and graphics, fees and expenses of any consultants engaged in
connection with the road show presentations with the prior approval of the Company, travel and
lodging expenses of the representatives and officers of the Company and any such consultants, and
the cost of any aircraft chartered in connection with the road show, (ix) the document production
charges and expenses associated with printing this Agreement and (x) all other costs and expenses
incident to the performance of the obligations of the Company hereunder for which provision is not
otherwise made in this Section. It is understood, however, that except as provided in this Section
6(n), Section 8 and the last paragraph of Section 10, the Underwriters will pay all of their costs
and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on
resale of any of the Shares by them and any advertising expenses connected with any offers they may
make.
(o) The Company also covenants with each Underwriter that, without the prior joint written
consent of Xxxxxx Xxxxxxx & Co. Incorporated and X.X. Xxxxxx Securities Inc. on behalf of the
Underwriters, it will not, during the period
ending 90 days after the date of the Prospectus, (1) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to
18
sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or
indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock, or (2) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, in
cash or otherwise or (3) file any registration statement with the Commission relating to the
offering of any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock. The foregoing sentence shall not apply to (a) the Shares to be sold
hereunder, (b) the issuance by the Company of shares of Common Stock upon the exercise of an option
or warrant or the conversion of a security outstanding on the date hereof as to which the
Underwriters have been advised in writing, (c) the establishment of a trading plan pursuant to Rule
10b5-1 under the Exchange Act, for the transfer of shares of Common Stock; provided that such plan
does not provide for the transfer of Common Stock during the 90-day restricted period, (d) the
issuance of Series A Junior Participating Preferred Stock and Series B Junior Participating
Preferred Stock (or the issuance of shares of Common Stock upon the conversion of either of both of
such series of Preferred Stock) pursuant to the Company’s Amended and Restated Rights Agreement,
dated as of December 17, 2008, between the Company and Mellon Investor Services LLC, as rights
agent, or (e) any shares of Common Stock issued, or options to purchase Common Stock granted,
pursuant to employee benefit plans or director compensation plans of the Company existing on the
date hereof.
7. Covenants of the Underwriters. Each Underwriter severally covenants with the Company not
to take any action that would result in the Company being required to file with the Commission
under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that
otherwise would not be required to be filed by the Company thereunder, but for the action of the
Underwriter.
8. Indemnity and Contribution.
(a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any,
who controls any Underwriter within the meaning of either Section 15 of the Securities Act or
Section 20 of the Exchange Act and each affiliate of any Underwriter within the meaning of Rule 405
under the Securities Act from and against any and all losses, claims, damages and liabilities
(including, without limitation, any legal or other expenses reasonably incurred in connection with
defending or investigating any such action or claim) caused by any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement or any amendment
thereof, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing
19
prospectus as defined in Rule 433(h) under the Securities Act, any Company information that
the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, or
the Prospectus or any amendment or supplement thereto, or caused by any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, except insofar as such losses, claims, damages or liabilities
are caused by any such untrue statement or omission or alleged untrue statement or omission based
upon information relating to any Underwriter furnished to the Company in writing by such
Underwriter through you expressly for use therein.
(b) Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, its directors, its officers who sign the Registration Statement and each person, if any,
who controls the Company within the meaning of either Section 15 of the Securities Act or
Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to
such Underwriter, but only with reference to information relating to such Underwriter furnished to
the Company in writing by such Underwriter through you expressly for use in the Registration
Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing
prospectus or the Prospectus or any amendment or supplement thereto.
(c) In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b),
such person (the “indemnified party”) shall promptly notify the person against whom such indemnity
may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the
indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to
represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In
any such proceeding, any indemnified party shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the
indemnifying party and the indemnified party shall have mutually agreed to the retention of such
counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include
both the indemnifying party and the indemnified party and representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interests between them.
It is understood that the indemnifying party shall not, in respect of the legal expenses of any
indemnified party in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all such indemnified parties and that all such fees and expenses shall be
reimbursed as they are incurred. Such firm shall be designated in writing jointly by Xxxxxx
Xxxxxxx & Co. Incorporated and X.X. Xxxxxx Securities Inc., in the case of parties
20
indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified
pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a
final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party
from and against any loss or liability by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying
party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the
second and third sentences of this Section 8(c), the indemnifying party agrees that it shall be
liable for any settlement of any proceeding effected without its written consent if (i) such
settlement is entered into more than 30 days after receipt by such indemnifying party of the
aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party
in accordance with such request prior to the date of such settlement. No indemnifying party shall,
without the prior written consent of the indemnified party, effect any settlement of any pending or
threatened proceeding in respect of which any indemnified party is or could have been a party and
indemnity could have been sought hereunder by such indemnified party, unless such settlement
includes an unconditional release of such indemnified party from all liability on claims that are
the subject matter of such proceeding.
(d) To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to
an indemnified party or insufficient in respect of any losses, claims, damages or liabilities
referred to therein, then each indemnifying party under such Section 8(a) or 8(b), as the case may
be, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid
or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i)
in such proportion as is appropriate to reflect the relative benefits received by the Company on
the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the
allocation provided by Section 8(d)(i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in Section 8(d)(i) above
but also the relative fault of the Company on the one hand and of the Underwriters on the other
hand in connection with the statements or omissions that resulted in such losses, claims, damages
or liabilities, as well as any other relevant equitable considerations. The relative benefits
received by the Company on the one hand and the Underwriters on the other hand in connection with
the offering of the Shares shall be deemed to be in the same respective proportions as the net
proceeds from the offering of the Shares (before deducting expenses) received by the Company and
the total underwriting discounts and commissions received by the Underwriters, in each case as set
forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of
the Shares. The relative fault of the Company on the one hand and the Underwriters on the other
hand shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates
to
21
information supplied by the Company or by the Underwriters and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Underwriters’ respective obligations to contribute pursuant to this Section 8 are several in
proportion to the respective number of Shares they have purchased hereunder, and not joint.
(e) The Company and the Underwriters agree that it would not be just or equitable if
contribution pursuant to this Section 8 were determined by pro rata allocation (even if the
Underwriters were treated as one entity for such purpose) or by any other method of allocation that
does not take account of the equitable considerations referred to in Section 8(d). The amount paid
or payable by an indemnified party as a result of the losses, claims, damages and liabilities
referred to in Section 8(d) shall be deemed to include, subject to the limitations set forth above,
any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this
Section 8, no Underwriter shall be required to contribute any amount in excess of the amount by
which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any indemnified party at
law or in equity.
(f) The indemnity and contribution provisions contained in this Section 8 and the
representations, warranties and other statements of the Company contained in this Agreement shall
remain operative and in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any Underwriter, any person controlling any
Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or
directors or any person controlling the Company and (iii) acceptance of and payment for any of the
Shares.
9. Termination. The Underwriters may terminate this Agreement by notice given by you to the
Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)
trading generally shall have been suspended or materially limited on, or by, as the case may be,
any of the New York Stock Exchange or the NASDAQ Global Market, (ii) trading of any securities of
the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a
material disruption in securities settlement, payment or clearance services in the United States
shall have occurred, (iv) any moratorium on commercial banking activities shall have been declared
by federal
22
or New York state authorities or (v) there shall have occurred any outbreak or escalation of
hostilities, or any change in financial markets or any calamity or crisis that, in your judgment,
is material and adverse and which, singly or together with any other event specified in this
clause (vi), makes it, in your judgment, impracticable or inadvisable to proceed with the offer,
sale or delivery of the Shares on the terms and in the manner contemplated in the Time of Sale
Prospectus or the Prospectus.
10. Effectiveness; Defaulting Underwriters. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
If, on the Closing Date or an Option Closing Date, as the case may be, any one or more of the
Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase
hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or
Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate
number of the Shares to be purchased on such date, the other Underwriters shall be obligated
severally in the proportions that the number of Firm Shares set forth opposite their respective
names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of
all such non-defaulting Underwriters, or in such other proportions as you may specify, to purchase
the Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase on such date; provided that in no event shall the number of Shares that any Underwriter
has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an
amount in excess of one-ninth of such number of Shares without the written consent of such
Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail or refuse to
purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default
occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased on such date,
and arrangements satisfactory to you and the Company for the purchase of such Firm Shares are not
made within 36 hours after such default, this Agreement shall terminate without liability on the
part of any non-defaulting Underwriter or the Company. In any such case either you or the Company
shall have the right to postpone the Closing Date, but in no event for longer than seven days, in
order that the required changes, if any, in the Registration Statement, in the Time of Sale
Prospectus, in the Prospectus or in any other documents or arrangements may be effected. If, on an
Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional
Shares and the aggregate number of Additional Shares with respect to which such default occurs is
more than one-tenth of the aggregate number of Additional Shares to be purchased on such Option
Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their
obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date or
(ii) purchase not less than the number of Additional Shares that such non-defaulting Underwriters
would have been obligated to purchase in the absence of such default. Any action taken under this
23
paragraph shall not relieve any defaulting Underwriter from liability in respect of any
default of such Underwriter under this Agreement.
If this Agreement shall be terminated by the Underwriters, or any of them, because of any
failure or refusal on the part of the Company to comply with the terms or to fulfill any of the
conditions of this Agreement, or if for any reason the Company shall be unable to perform its
obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters
as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket
expenses (including the fees and disbursements of their counsel) reasonably incurred by such
Underwriters in connection with this Agreement or the offering contemplated hereunder.
11. Entire Agreement.
(a) This Agreement, together with any contemporaneous written agreements and any prior written
agreements (to the extent not superseded by this Agreement) that relate to the offering of the
Shares, represents the entire agreement between the Company and the Underwriters with respect to
the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the
conduct of the offering, and the purchase and sale of the Shares.
(b) The Company acknowledges that in connection with the offering of the Shares: (i) the
Underwriters have acted at arms length, are not agents of, and owe no fiduciary duties to, the
Company or any other person; (ii) the Underwriters owe the Company only those duties and
obligations set forth in this Agreement and prior written agreements (to the extent not superseded
by this Agreement), if any; and (iii) the Underwriters may have interests that differ from those of
the Company. The Company waives to the full extent permitted by applicable law any claims it may
have against the Underwriters arising from an alleged breach of fiduciary duty in connection with
the offering of the Shares.
12. Counterparts. This Agreement may be signed in two or more counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument.
13. Applicable Law. This Agreement shall be governed by and construed in accordance with the
internal laws of the State of New York.
14. Headings. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement.
24
15. Notices. All communications hereunder shall be in writing and effective only upon receipt
and if to the Underwriters shall be delivered, mailed or sent to you in care of Xxxxxx
Xxxxxxx & Co. Incorporated, 0000 Xxxxxxxx, Xxx Xxxx, Xxx Xxxx 00000 (fax: 000-000-0000), Attention:
Equity Syndicate Desk, with a copy to the Legal Department and in care of X.X. Xxxxxx Securities
Inc., 000 Xxxxxxx Xxx, Xxx Xxxx, Xxx Xxxx 00000 (fax: 000-000-0000), Attention: Investment Grade
Syndicate Desk; and if to the Company shall be delivered, mailed or sent to Xxxxxxx Incorporated,
000 Xxxxx Xxxxxxx Xxxx, Xxxxxx, Xxxxxxxxxxx 00000-0000 (fax: 000-000-0000); Attention: Xxxxx X.
Xxxx, Senior Vice President and Chief Financial Officer, and Xxxxxxx X. Xxxxxx, Vice President,
General Counsel and Secretary.
Very truly yours, XXXXXXX INCORPORATED |
||||
By: | /s/ Xxxxx Xxxx | |||
Name: | Xxxxx X. Xxxx | |||
Title: | Senior Vice President and Chief Financial Officer | |||
Accepted as of the date hereof:
XXXXXX XXXXXXX & CO. INCORPORATED
X.X. XXXXXX SECURITIES INC.
X.X. XXXXXX SECURITIES INC.
Acting severally on behalf of themselves and the several
Underwriters named in Schedule I hereto. |
||||||
By | XXXXXX XXXXXXX & CO. INCORPORATED | |||||
By: | /s/ Xxxx Xxxxx | |||||
Name: | Xxxx X. Xxxxx | |||||
Title: | Managing Director | |||||
By | X.X. XXXXXX SECURITIES INC. | |||||
By: | /s/ Xxxx Xxxxxxx | |||||
Name: | Xxxx X. Xxxxxxx | |||||
Title: | Managing Director |
25
SCHEDULE I
Number of Firm Shares | ||||
Underwriter | To Be Purchased | |||
Xxxxxx Xxxxxxx & Co. Incorporated |
1,105,000 | |||
X.X. Xxxxxx Securities Inc. |
975,000 | |||
BNY Mellon Capital Markets, LLC |
130,000 | |||
HSBC Securities (USA) Inc. |
130,000 | |||
Jesup & Xxxxxx Securities Corporation |
130,000 | |||
Xxxxx Fargo Securities, LLC |
130,000 | |||
Total: |
2,600,000 | |||
I-1
SCHEDULE II
Time of Sale Prospectus
1. | Preliminary Prospectus issued on October 26, 2009 (consisting of the preliminary prospectus supplement dated October 26, 2009 and the Base Prospectus dated May 28, 2008) | ||
2. | Rule 134 Term Sheet |
II-1
EXHIBIT A
RULE 134 TERM SHEET
Xxxxxxx Incorporated
2,600,000 Shares
Class B Common Stock
2,600,000 Shares
Class B Common Stock
Issuer: |
Xxxxxxx Incorporated | |
Symbol: |
HUB.B | |
Size: |
$111,800,000 | |
Shares offered: |
2,600,000 shares of Class B Common Stock | |
Over-allotment option: |
Option to purchase additional 390,000 shares | |
Price to public: |
$43.00 per share | |
Underwriting discount: |
$2.0425 per share | |
Trade date: |
October 28, 2009 | |
Closing date: |
November 3, 2009 (T+4) | |
CUSIP: |
443510 20 1 | |
Underwriters: |
Xxxxxx Xxxxxxx & Co. Incorporated | |
X.X. Xxxxxx Securities Inc. | ||
BNY Mellon Capital Markets, LLC | ||
HSBC Securities (USA) Inc | ||
Jesup & Xxxxxx Securities Corporation | ||
Xxxxx Fargo Securities, LLC |
Copies of the prospectus related to this offering may be obtained from Xxxxxx Xxxxxxx & Co.
Incorporated, Attention: Prospectus Department, 000 Xxxxxx Xxxxxx, 0xx Xxxxx, Xxx Xxxx, Xxx Xxxx
00000 (email address: xxxxxxxxxx@xxxxxxxxxxxxx.xxx) or by calling 1-866-718-1649, or X.X. Xxxxxx
Securities Inc., Attention: Broadridge Financial Solutions, 0000 Xxxx Xxxxxx Xxx, Xxxxxxxx, Xxx
Xxxx 00000, or by calling 1-631-254-1735.
This communication shall not constitute an offer to sell or the solicitation of any offer to buy,
nor shall there be any sale of the securities in any state in such offer,
A-1
solicitation or sale
would be unlawful prior to the registration or qualification under the securities law of any such
state.
A-2
EXHIBIT B
FORM OF OPINION OF CONNECTICUT
COUNSEL FOR THE COMPANY
COUNSEL FOR THE COMPANY
1. The Company is in legal existence under the laws of the State of Connecticut, and the
Company has the corporate power and authority to own its property and to conduct its business as
described in the Time of Sale Prospectus and the Prospectus.
2. Xxxxxxx Lighting, Inc. is in legal existence under the laws of the State of Connecticut.
3. The authorized capital stock of the Company conforms as to legal matters to the description
thereof contained in each of the Time of Sale Prospectus and the Prospectus.
4. The Shares have been duly authorized and, when issued and delivered in accordance with the
terms of this Agreement, will be validly issued, fully paid and non-assessable, and the issuance of
such Shares will not be subject to any preemptive rights under Applicable Laws (as defined in such
counsel’s opinion).
5. This Agreement has been duly authorized, executed and delivered by the Company.
6. The statements relating to legal matters, documents or proceedings included in the Time of
Sale Prospectus and the Prospectus under the caption “Description of Capital Stock” fairly
summarize in all material respects such matters, documents or proceedings.
7. The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement (including, without limitation, the issuance and sale of the
Shares) will not contravene or result in a breach or violation of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any lien, charge or
encumbrance upon any property or assets of the Company pursuant to the Certificate of Incorporation
or the By-Laws or Applicable Laws known to such counsel to be customarily applicable to
transactions of this nature.
8. No consent, approval, authorization or order of, or registration or qualification with, any
Connecticut court or governmental or regulatory agency, authority or body is required under
Applicable Laws for the execution and delivery of this Agreement by the Company and performance by
the Company of its obligations thereunder (including, without limitation, the issuance and sale of
B-1
the Shares), except as may be required by the securities or blue sky laws of the
State of Connecticut in connection with the offer and sale of the Shares, as to which such
counsel need express no opinion.
B-2
EXHIBIT C
FORM OF OPINION AND DISCLOSURE LETTER
OF COUNSEL FOR THE COMPANY
OF COUNSEL FOR THE COMPANY
Opinion:
1. Each of the Delaware Subsidiaries (as defined in such counsel’s opinion) is a corporation
under the DGCL with corporate power and authority to own its properties and to conduct its business
as described in the Registration Statement, the Preliminary Prospectus (as defined in such
counsel’s opinion) and the Prospectus. With the Underwriters’ consent, based solely on
certificates from public officials, such counsel confirms that each of the Delaware Subsidiaries is
validly existing and in good standing under the laws of the State of Delaware.
2. The execution and delivery of this Agreement by the Company and the issuance and sale of
the Shares by the Company to the several Underwriters pursuant to this Agreement do not on the date
hereof:
(i) result in the breach of or a default under any of the Specified Agreements (as
defined in such counsel’s opinion); or
(ii) violate any federal or New York statute, rule or regulation applicable to the
Company; or
(iii) require any consents, approvals, or authorizations to be obtained by the Company
from, or any registrations, declarations or filings to be made by the Company with,
any governmental authority under any federal or New York statute, rule or regulation
applicable to the Company that have not been obtained or made.
3. The Registration Statement has become effective under the Securities Act. With the
Underwriters’ consent, based solely on a telephonic confirmation by a member of the Staff of the
Commission on the date hereof, such counsel confirms that no stop order suspending the
effectiveness of the Registration Statement has been issued under the Securities Act and no
proceedings therefor have been initiated by the Commission. The Preliminary Prospectus has been
filed in accordance with Rule 424(b) under the Securities Act and the Prospectus has been filed in
accordance with Rule 424(b) and Rule 430B under the Securities Act.
4. The Registration Statement at May 28, 2008, including the information deemed to be a part
thereof pursuant to Rule 430B under the Securities Act, the Preliminary Prospectus, as of its date,
and the Prospectus, as of its date, in each case including the portions of the Incorporated
Documents (as defined in such counsel’s opinion) responsive to the item requirements of Form S-3
incorporated by reference therein at such date, each appeared on its face to be
C-1
appropriately
responsive in all material respects to the applicable form requirements for registration statements
on Form S-3 under the Securities Act and
the rules and regulations of the Commission thereunder; it being understood, however, that
such counsel need express no view with respect to Regulation S-T or the financial statements,
schedules, or other financial data included in, incorporated by reference in, or omitted from the
Registration Statement or the Prospectus. For purposes of this paragraph, such counsel may assume
that the statements made in the Registration Statement and the Prospectus are correct and complete.
5. The statements in the Preliminary Prospectus and the Prospectus under the caption
“Underwriting,” insofar as they purport to describe or summarize certain provisions of this
Agreement, are accurate descriptions or summaries in all material respects.
6. The Company is not, and immediately after giving effect to the sale of the Shares in
accordance with this Agreement and the application of the proceeds as described in the Prospectus
under the caption “Use of Proceeds,” will not be required to be registered as an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.
C-2
Disclosure Letter:
No facts have come to such counsel’s attention that caused it to believe that:
1. The Registration Statement, at the time it became effective on May 28, 2008,
including the information deemed to be a part of the Registration Statement pursuant to Rule 430B
under the Securities Act (together with the Incorporated Documents at that time), contained an
untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary to make the statements therein not misleading;
2. The Preliminary Prospectus, as of October ___, 2009 (together with the Incorporated
Documents at that date and the Pricing Information Annex (as defined in such counsel’s opinion)),
contained an untrue statement of a material fact or omitted to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not
misleading; or
3. The Prospectus, as of its date or as of the date hereof (together with the Incorporated
Documents at those dates), contained or contains an untrue statement of a material fact or omitted
or omits to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.
C-3
EXHIBIT D
FORM OF TAX OPINION OF COUNSEL FOR THE COMPANY
Such counsel hereby confirms that the statements in the Preliminary Prospectus and the
Prospectus under the caption “Certain U.S. Federal Income Tax Considerations for Non-U.S. Holders,”
insofar as such statements purport to constitute summaries of United States federal income tax law
and regulations or legal conclusions with respect thereto, constitute accurate summaries of the
matters described therein in all material respects.
D-1
EXHIBIT E
FORM OF LOCK-UP LETTER
October ___, 2009
Xxxxxx Xxxxxxx & Co. Incorporated
X.X. Xxxxxx Securities Inc.
X.X. Xxxxxx Securities Inc.
As Representatives of the
several Underwriters
several Underwriters
c/o Morgan Xxxxxxx & Co. Incorporated
0000 Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
0000 Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
X.X. Xxxxxx Securities Inc.
000 Xxxxxxx Xxx
Xxx Xxxx, Xxx Xxxx 00000
000 Xxxxxxx Xxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
The undersigned understands that Xxxxxx Xxxxxxx & Co. Incorporated (“Xxxxxx Xxxxxxx”) and X.X.
Xxxxxx Securities Inc. (“X.X. Xxxxxx”) propose to enter into an Underwriting Agreement (the
“Underwriting Agreement”) with Xxxxxxx Incorporated, a Connecticut corporation (the “Company”),
providing for the public offering (the “Public Offering”) by the several underwriters, listed in
Schedule I to the Underwriting Agreement, including Xxxxxx Xxxxxxx and X.X. Xxxxxx (the
“Underwriters”), of up to 3,000,000 shares of the Class B Common Stock, par value $.01, of the
Company (the Class B Common Stock, together with the Class A Common Stock, par value $.01, of the
Company, is referred to herein as the “Common Stock”).
To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, except as
specifically contemplated by the final prospectus related to the proposed Public Offering (the
“Prospectus”), without the prior written consent of Xxxxxx Xxxxxxx and X.X. Xxxxxx on behalf of the
Underwriters, it will not, during the period commencing on the date hereof and ending 90 days after
the date of the Prospectus, (1) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to
E-1
sell, grant any option, right or warrant to
purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common
Stock or any securities
convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or
other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the Common Stock or such other securities, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities,
in cash or otherwise. The foregoing sentence shall not apply to (a) transactions relating to
shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common
Stock, acquired in open market transactions after the completion of the Public Offering, provided
that no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), shall be required or shall be voluntarily made in connection with subsequent sales
of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock
acquired in such open market transactions; (b) transfers of shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock (i) as a bona fide gift, (ii) to
the undersigned’s affiliates or (iii) by will or the laws of descent and distribution, provided
that (i) each transferee or distributee shall sign and deliver a lock-up agreement substantially in
the form of this letter and (ii) no filing under Section 16(a) of the Exchange Act, reporting a
reduction in beneficial ownership of shares of Common Stock or such other securities, shall be
required or shall be voluntarily made during the restricted period referred to in the foregoing
sentence; (c) distributions of shares of Common Stock or any such other security to limited
partners or stockholders of the undersigned, provided that (i) each transferee or distributee shall
sign and deliver a lock-up letter substantially in the form of this letter and (ii) no filing under
Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of
Common Stock or such other securities, shall be required or shall be voluntarily made during the
restricted period referred to in the foregoing sentence; (d) the establishment of a trading plan
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock or such
other securities, provided that such plan does not provide for the transfer of Common Stock or such
other securities during the restricted period; or (e) sales of shares of Common Stock upon vesting
of restricted stock units, but only to the extent necessary to pay withholding tax upon vesting.
In addition, the undersigned agrees that, without the prior written consent of Xxxxxx Xxxxxxx and
X.X. Xxxxxx on behalf of the Underwriters, it will not, during the period commencing on the date
hereof and ending 90 days after the date of the Prospectus, make any demand for or exercise any
right with respect to, the registration of any shares of Common Stock or any security convertible
into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to
the entry of stop transfer instructions with the Company’s transfer agent and registrar against the
transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing
restrictions.
2
[For the avoidance of doubt, the restriction on transfer contained herein shall not apply to
securities of the Company beneficially owned by the Xxxxxxx Trust or the Roche Trust for which the
undersigned serves as a trustee.]
The undersigned understands that the Company and the Underwriters are relying upon this
lock-up agreement in proceeding toward consummation of the Public Offering. The undersigned
further understands that this lock-up agreement is irrevocable and shall be binding upon the
undersigned’s heirs, legal representatives, successors and assigns.
Whether or not the Public Offering actually occurs depends on a number of factors, including
market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
Very truly yours, |
||||
(Name) | ||||
(Address) | ||||
3